OSRHW
Bellevue Life Sciences Acquisition Corp - Warrants (09/02/2028) (OSRHW)
NASDAQ • $0.06-19.57%
- Symbol
- OSRHW
- Exchange
- NASDAQ
- Sector
- Industry
- Price
- $0.06
- Daily Change
- -19.57%
- Market Cap
- N/A
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $0.08
- 52W Low
- $0.06
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.86
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based i…
Company websiteResearch OSRHW on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.